Study objectives in clinical trials in older patients with solid malignancies: do we measure what matters?
Ellen R M ScheepersL H van Huis-TanjaM H Emmelot-VonkM E HamakerPublished in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2021)
Despite a slight incremental trend over the past 15 years, PROs appear to be underrepresented in clinical trials which include patients with a solid malignancy. In order to provide physicians and older patients with cancer realistic information about the impact of chemo- or immunotherapy on quality of life or functioning, researchers should strongly consider including PROs in their future clinical trials.